Browse Tag

PIK3CA mutation

March 1, 2021March 1, 2021

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

Novartis announced the Health Sciences Authority (HSA) has approved* Piqray®, an α-specific class I phosphatidylinositol-3-kinase (PIK3CA) inhibitor, for the treatment of postmenopausal women, and men, with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2-) negative, advanced breast cancer with a PIK3CA mutation

Pharmaceutical News

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

March 1, 2021March 1, 2021

Novartis announced the Health Sciences Authority (HSA) has approved* Piqray®, an α-specific class I phosphatidylinositol-3-kinase (PIK3CA) inhibitor, for the treatment of

Go toTop

<img src="http://www.pharmamirror.com/wp-content/uploads/2018/01/Pharma-Mirror.png" alt="Mobile Logo" width="330" height="77">

PIK3CA mutation

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval